Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 460-465

  Patel, N ^a   Scheetz, M H ^b,c   Drusano, G L ^d   Lodise, T P ^a,d  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Department of Pharmacy Practice   (United States)

^c NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^d ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOSAGE SCHEDULE COMPARISON; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG INFUSION; FEMALE; HOSPITAL INFECTION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OPTIMAL DRUG DOSE; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL;

AREA UNDER CURVE; BAYES THEOREM; CROSS INFECTION; DRUG COMBINATIONS; FEMALE; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, STATISTICAL; MONTE CARLO METHOD; PENICILLANIC ACID; PIPERACILLIN; PNEUMONIA, PNEUMOCOCCAL; REPRODUCIBILITY OF RESULTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 73849144571     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00296-09     Document Type: Article

References (29)

1. Anonymous. 2009. Zosyn - full prescribing information. Wyeth Pharmaceuticals Inc., Philadelphia, PA.
2. Aronoff, G. R., R. S. Sloan, M. E. Brier, and F. C. Luft. 1983. The effect of piperacillin dose on elimination kinetics in renal impairment. Eur. J. Clin. Pharmacol. 24:543-547.
3. Barza, M., and L. Weinstein. 1976. Pharmacokinetics of the penicillins in man. Clin. Pharmacokinet. 1:297-308.
4. Cars, O. 1997. Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagn. Microbiol. Infect. Dis. 27:29-33.
5. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
6. Craig, W. 1993. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur. J. Clin. Microbiol. Infect. Dis. 12(Suppl. 1):S6-S8.
7. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
8. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
9. D'Argenio, D. Z., and A. Schumitzky. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Programs Biomed. 9:115-134.
10. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289-300.
11. Hanberger, H. 1992. Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time. Scand. J. Infect. Dis. Suppl. 81:1-52.
12. Hyatt, J. M., P. S. McKinnon, G. S. Zimmer, and J. J. Schentag. 1995. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet. 28:143-160.
13. Kim, A., C. A. Sutherland, J. L. Kuti, and D. P. Nicolau. 2007. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy 27: 1490-1497.
14. Kim, M. K., B. Capitano, H. M. Mattoes, D. Xuan, R. Quintiliani, C. H. Nightingale, and D. P. Nicolau. 2002. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Pharmacotherapy 22:569-577.
15. Kinzig, M., F. Sorgel, B. Brismar, and C. E. Nord. 1992. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob. Agents Chemother. 36:1997-2004.
16. Kollef, M. H., G. Sherman, S. Ward, and V. J. Fraser. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.
17. Kuti, J. L., C. H. Nightingale, R. Quintiliani, and D. P. Nicolau. 2002. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn. Microbiol. Infect. Dis. 44:51-57.
18. Leary, R. J., A. Schumitzky, and M. van Guilder. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. In Proceedings, Fourteenth IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society, Bethesda, MD.
19. Lodise, T. P., Jr., B. Lomaestro, K. A. Rodvold, L. H. Danziger, and G. L. Drusano. 2004. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob. Agents Chemother. 48:4718-4724.
20. Lodise, T. P., B. Lomaestro, A. Kwa, and G. L. Drusano. 2007. Pharmacodynamics (PD) of extended infusion piperacillin/tazobactam (EI-PIP) against Pseudomonas aeruginosa, abstr. 449. Abstr. 45th Annu. Meet. Infect. Dis. Soc. Am. Infectious Disease Society of America, San Diego, CA.
21. Lodise, T. P., B. M. Lomaestro, and G. L. Drusano. 2006. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 26:1320-1332.
22. Masuda, G., S. Tomioka, H. Uchida, and M. Hasegawa. 1977. Bacteriostatic and bactericidal activities of selected beta-lactam antibiotics studied on agar plates. Antimicrob. Agents Chemother. 11:376-382.
23. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, F. A. Wong, and M. Corrado. 1998. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob. Agents Chemother. 42:1098-1104.
24. Reese, A. M., C. R. Frei, and D. S. Burgess. 2005. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms. Int. J. Antimicrob. Agents 26:114-119.
25. Sörgel, F., and M. Kinzig. 1994. Pharmacokinetic characteristics of piperacillin/ tazobactam. Intensive Care Med. 20(Suppl. 3):S14-S20.
26. Strayer, A. H., D. H. Gilbert, P. Pivarnik, A. A. Medeiros, S. H. Zinner, and M. N. Dudley. 1994. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob. Agents Chemother. 38:2351-2356.
27. Sullivan, M. C., C. H. Nightingale, R. Quintiliani, and K. Sweeney. 1993. Comparison of the pharmacokinetic and pharmacodynamic activity of piperacillin and mezlocillin. Pharmacotherapy 13:607-612.
28. Tam, V. H., E. A. Gamez, J. S. Weston, L. N. Gerard, M. T. Larocco, J. P. Caeiro, L. O. Gentry, and K. W. Garey. 2008. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillintazobactam: implications on the appropriateness of the resistance breakpoint. Clin. Infect. Dis. 46:862-867.
29. Van der Auwera, P., V. Duchateau, C. Lambert, M. Husson, M. Kinzig, and F. Sorgel. 1993. Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid. Antimicrob. Agents Chemother. 37:1860-1868.